EUVIMEDEUVIMED entdecken
Open Access · CC BY-SA 4.0

ADVANCED NANOCARRIERS FOR CONTROLLED DRUG AND GENE DELIVERY IN CHRONIC DISEASES

Ren Suzuki, Daiki Nishida, Nila Trisna Yulianti

Journal of Biomedical and Techno Nanomaterials · 19.04.2026 · 3 (2) · 98-110

DOI: 10.70177/jbtn.v3i2.3585 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Biomedical and Techno Nanomaterials, online erschienen am 19.04.2026. Verfasst von Ren Suzuki und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic diseases such as cancer, cardiovascular diseases, and neurodegenerative disorders pose significant treatment challenges due to their complexity and resistance to conventional therapies. Nanocarriers, as advanced drug and gene delivery systems, offer a promising solution to address these challenges by providing controlled release, improved targeting, and enhanced therapeutic efficacy. The ability to design nanocarriers that are biocompatible, stable, and capable of precise targeting to diseased tissues holds potential for revolutionizing the treatment of chronic diseases. This study aims to explore the design, development, and evaluation of advanced nanocarriers for controlled drug and gene delivery in chronic diseases. The research focuses on evaluating the efficacy of various nanocarriers, including liposomes, dendrimers, and nanoparticles, in improving drug bioavailability, targeting precision, and therapeutic outcomes in chronic disease models. The research utilizes in vitro cell culture studies and in vivo animal models to assess the effectiveness of different nanocarriers. Characterization techniques, including dynamic light scattering (DLS), transmission electron microscopy (TEM), and drug release assays, are used to evaluate the properties and performance of the nanocarriers. The study demonstrates that advanced nanocarriers significantly improve drug delivery efficiency, reduce systemic toxicity, and enhance therapeutic outcomes in chronic disease models. Gene delivery using nanocarriers also shows promising results in terms of targeted therapy. Advanced nanocarriers are a promising tool for controlled drug and gene delivery, offering potential breakthroughs in the treatment of chronic diseases by improving precision and minimizing side effects.

Zitieren

APA

Suzuki, R., Nishida, D., & Yulianti, N. T. (2026). ADVANCED NANOCARRIERS FOR CONTROLLED DRUG AND GENE DELIVERY IN CHRONIC DISEASES. Journal of Biomedical and Techno Nanomaterials, 3(2), 98-110. https://doi.org/10.70177/jbtn.v3i2.3585

Vancouver

Suzuki R, Nishida D, Yulianti NT. ADVANCED NANOCARRIERS FOR CONTROLLED DRUG AND GENE DELIVERY IN CHRONIC DISEASES. Journal of Biomedical and Techno Nanomaterials. 2026;3(2):98-110. doi:10.70177/jbtn.v3i2.3585

BibTeX
@article{Suzuki2026,
  author = {Suzuki, Ren and Nishida, Daiki and Yulianti, Nila Trisna},
  title = {ADVANCED NANOCARRIERS FOR CONTROLLED DRUG AND GENE DELIVERY IN CHRONIC DISEASES},
  journal = {Journal of Biomedical and Techno Nanomaterials},
  year = {2026},
  volume = {3},
  number = {2},
  pages = {98--110},
  doi = {10.70177/jbtn.v3i2.3585}
}
Kostenlos starten →